stockholm 2018: status of mrd testing in multiple myeloma
Published 6 years ago • 459 plays • Length 8:31Download video MP4
Download video MP3
Similar videos
-
4:10
how does minimal residual disease (mrd) testing affect treatment decisions?
-
10:56
stockholm 2018: what is the role of mass spectrometry in multiple myeloma
-
58:26
myeloma updates 2018: best of asco/eha/imwg
-
10:54
stockholm 2018: new drugs in multiple myeloma
-
3:32
how does the fda approval of ngs to test for mrd in multiple myeloma affect patients?
-
4:01
if a myeloma patient has mrd-negative status, does that mean that patient is cured?
-
3:26
how valuable is minimal residual disease testing for myeloma patients?
-
57:47
faqs from the international myeloma society annual meeting
-
3:43
mrd-guided treatment cessation in multiple myeloma
-
3:17
what new tests are on the horizon for myeloma monitoring?
-
2:43
24-hour urine testing does not add value to multiple myeloma response assessments
-
5:15
is mrd testing routinely recommended for myeloma patients?
-
8:38
stockholm 2018: role of crispr gene editing in multiple myeloma
-
3:21
is there a new highly sensitive blood test to detect minimal residual disease?
-
2:28
what is minimal residual disease (mrd) and how can it help speed up new myeloma drug approvals?
-
4:30
mrd testing is a reliable endpoint for the assessment of deep responses in myeloma clinical trials
-
1:01:37
imwg conference series stockholm 2018
-
3:06
what is minimal residual testing in multiple myeloma?
-
4:53
clinical implications of loss of minimal residual disease (mrd) negativity in multiple myeloma
-
1:04
the value of mrd in transplant-ineligible patients with multiple myeloma
-
1:59
mrd negativity as predictors of early relapse in transplant-eligible multiple myeloma patients
-
2:46
are mass spectrometry and next-generation flow useful tests to evaluate minimal residual disease?